All In Biotech

Drug Trial Radar · NCT06874621

VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

VY7523-102: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Ascending Intravenous Doses of VY7523 in Participants With Early Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Mar 3, 2025

Primary completion

Oct 13, 2026

Study completion May 2027

Sponsor

Lead sponsor
Voyager TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.

Conditions

  • Alzheimer's Disease (AD)

Interventions

  • VY7523Drug

    VY7523 is a recombinant humanized immunoglobulin gamma 4 (IgG4) monoclonal antibody targeting human pathological tau

  • Placebo ComparatorDrug

    Matching placebo to VY7523

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Characterization of the safety and tolerability of VY7523 in participants with early ADTime frame: Cohorts 1 and 2: up to 6 months Cohort 3: up to 12 months

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • VYGR Site 840018

    Los Angeles, California

  • VYGR Site 840016

    Orange, California

  • VYGR Site 840022

    San Francisco, California

  • VYGR Site 840008

    Stamford, Connecticut

  • VYGR Site 840005

    Delray Beach, Florida

  • VYGR Site 840021

    Fort Myers, Florida

  • VYGR Site 840010

    Lady Lake, Florida

  • VYGR Site 840015

    Miami, Florida

  • VYGR Site 840014

    Miami, Florida

  • VYGR Site 840024

    Miami, Florida

  • VYGR Site 840006

    Orlando, Florida

  • VYGR Site 840003

    Stuart, Florida

  • VYGR Site 840004

    The Villages, Florida

  • VYGR Site 840002

    Wellington, Florida

  • VYGR Site 840020

    Winter Park, Florida

  • VYGR Site 840007

    Decatur, Georgia

  • VYGR Site 840012

    Toms River, New Jersey

  • VYGR Site 840009

    Matthews, North Carolina

  • VYGR Site 840011

    Plymouth Meeting, Pennsylvania

  • VYGR Site 124002

    Ottawa, Ontario, Canada

  • VYGR Site 124001

    Toronto, Ontario, Canada

  • VYGR Site 124003

    Montreal, Quebec, Canada

  • VYGR Site 124004

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.